Proparacaine is a local anesthetic active pharmaceutical ingredient (API) belonging to the amino ester class of local anesthetics. It is primarily used as a topical ophthalmic anesthetic to temporarily numb the surface of the eye during ophthalmic examinations and procedures. Proparacaine is identified by CAS Number 499-67-2, with the molecular formula C16H26N2O3 and molecular weight 294.39 g/mol. Proparacaine is commonly used in pharmaceutical products in its hydrochloride salt form, Proparacaine Hydrochloride, which has CAS Number 5875-06-9 and molecular weight 330.80 g/mol.
Proparacaine is a synthetic benzoate ester with local anesthetic properties. It acts primarily by inhibiting voltage-gated sodium channels in nerve membranes, reducing sodium-ion influx and preventing the initiation and conduction of nerve impulses. Proparacaine Hydrochloride is commonly used in ophthalmic solutions, including products containing a 0.5% concentration of the hydrochloride salt.
The API is important for pharmaceutical manufacturing of topical ophthalmic anesthetic preparations used before procedures involving the eye.
Proparacaine has the following established chemical characteristics:
PubChem confirms the chemical identity and molecular characteristics of both Proparacaine and Proparacaine Hydrochloride.
Proparacaine is primarily used in ophthalmic pharmaceutical products as a topical local anesthetic.
Its applications include:
Proparacaine Hydrochloride is particularly common in ophthalmic formulations because the hydrochloride salt is the established pharmaceutical form used in marketed ophthalmic preparations.
Proparacaine produces local anesthesia by interacting with voltage-gated sodium channels in neuronal membranes. This inhibits sodium-ion influx and prevents the generation and propagation of action potentials, resulting in temporary loss of sensation at the site of application.
Quality control of Proparacaine API is important to establish identity, assay, purity, and consistency. For pharmaceutical applications, analytical testing should follow the applicable pharmacopoeial monograph and approved specification.
The USP Proparacaine Hydrochloride monograph provides a liquid-chromatographic assay procedure and identifies a proposed acceptance range of 98.0%–102.0%. The USP monograph also includes chromatographic identification and organic impurity testing.
Typical quality-control testing may include:
Proparacaine API manufacturing requires controlled chemical processing, qualified raw materials, purification, impurity control, drying, and validated analytical testing.
A quality-focused manufacturing process may include:
For Proparacaine Hydrochloride intended for ophthalmic pharmaceutical products, additional quality requirements may apply depending on the finished dosage form and intended use.
Proparacaine should be packed in suitable, tightly closed pharmaceutical containers that protect the material from moisture, contamination, light, and unsuitable environmental exposure.
Storage conditions should follow the applicable API specification and stability data. Appropriate packaging and controlled transportation help maintain the quality of the API during storage and distribution.
Documentation for Proparacaine API may include:
A reliable Proparacaine API manufacturing program should maintain controlled manufacturing processes, validated analytical methods, impurity monitoring, batch traceability, and appropriate pharmaceutical documentation.
For Proparacaine Hydrochloride, the USP monograph specifically addresses identity, assay, organic impurities, and other quality attributes. The USP proposal specifies 98.0%–102.0% for the chromatographic assay and removes the nonspecific melting-range test from the monograph in favor of more specific analytical controls.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |